Clinical Trials Protein Production Small Molecule 
Drug Target Review
NOVEMBER 1, 2023
The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. We support the drug discovery projects of the CCDD with assay development and screening, biophysics, structural biology and recombinant protein production.
Dark Matter Blog
JULY 16, 2021
My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. I was enticed by Arrakis’ founder Jen Petter to serve in one more operational role, leading the research group at Arrakis as the company launched as one of the first biotechs to target RNA with drug-like small molecules.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
OCTOBER 14, 2020
Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases.
The Pharma Data
MARCH 23, 2022
Unfortunately, in a Phase 3 clinical trial, treatment with remdesivir did not make a difference in mortality for Ebola virus disease patients. Without the stop sign, viral transcription no longer follows the correct order, which has a negative impact on viral protein production,” says Fang.
PLOS: DNA Science
AUGUST 8, 2024
Imprinting disorders can also result from differences between parental genders in gene expression – that is, protein production from the encoded information. We were able to show that (S)-PHA533533 had better uptake and that the same small molecule could be translated in human-derived neural cells, which is a huge finding.
Codon
MAY 30, 2023
Read Programming inactive RNA-binding small molecules into bioactive degraders. Read Engineered bacteria to accelerate wound healing: an adaptive, randomised, double-blind, placebo-controlled, first-in-human phase 1 trial. ‘OK’ to start clinical trials. Molecular Therapy. Nature Communications.
Codon
MAY 30, 2023
Read Programming inactive RNA-binding small molecules into bioactive degraders. Read Engineered bacteria to accelerate wound healing: an adaptive, randomised, double-blind, placebo-controlled, first-in-human phase 1 trial. ‘OK’ to start clinical trials. Molecular Therapy. Nature Communications.
Expert insights. Personalized for you.
96 
Let's personalize your content